Last reviewed · How we verify
SGLT2i+Metformin+Linagliptin
This triple-combination therapy reduces blood glucose through three complementary mechanisms: blocking renal glucose reabsorption (SGLT2i), enhancing insulin secretion and sensitivity (metformin), and inhibiting dipeptidyl peptidase-4 to prolong incretin action (linagliptin).
This triple-combination therapy reduces blood glucose through three complementary mechanisms: blocking renal glucose reabsorption (SGLT2i), enhancing insulin secretion and sensitivity (metformin), and inhibiting dipeptidyl peptidase-4 to prolong incretin action (linagliptin). Used for Type 2 diabetes mellitus.
At a glance
| Generic name | SGLT2i+Metformin+Linagliptin |
|---|---|
| Sponsor | Huazhong University of Science and Technology |
| Drug class | Combination antidiabetic agent (SGLT2 inhibitor + biguanide + DPP-4 inhibitor) |
| Target | SGLT2 transporter, mitochondrial complex I (metformin), dipeptidyl peptidase-4 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
SGLT2 inhibitors promote urinary glucose excretion independent of insulin. Metformin reduces hepatic glucose production and improves peripheral insulin sensitivity. Linagliptin, a DPP-4 inhibitor, increases active GLP-1 and GIP levels, stimulating glucose-dependent insulin secretion and suppressing glucagon. Together, these agents provide synergistic glycemic control with complementary mechanisms of action.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Genital mycotic infections
- Urinary tract infections
- Hypoglycemia
- Gastrointestinal disturbances
- Headache
- Nasopharyngitis
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes. (PHASE4)
- Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: